$79.57
+0.28
(+0.35%)▲
0.33%
Downside
Day's Volatility :0.63%
Upside
0.3%
19.92%
Downside
52 Weeks Volatility :24.56%
Upside
5.79%
Period | Dr. Reddy's Laboratories Ltd. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 4.47% | 7.5% | 0.0% |
6 Months | 8.81% | 6.9% | 0.0% |
1 Year | 20.2% | 20.9% | 0.0% |
3 Years | 18.14% | 21.0% | -21.1% |
Market Capitalization | 13.5B |
Book Value | $1769.05 |
Dividend Share | 40.0 |
Dividend Yield | 0.6% |
Earnings Per Share (EPS) | 3.98 |
PE Ratio | 20.02 |
PEG Ratio | 4.58 |
Wall Street Target Price | 85.7 |
Profit Margin | 19.26% |
Operating Margin TTM | 23.39% |
Return On Assets TTM | 10.93% |
Return On Equity TTM | 20.59% |
Revenue TTM | 288.5B |
Revenue Per Share TTM | 289.4 |
Quarterly Revenue Growth YOY | 13.900000000000002% |
Gross Profit TTM | 113.8B |
EBITDA | 79.5B |
Diluted Eps TTM | 3.98 |
Quarterly Earnings Growth YOY | -0.01 |
EPS Estimate Current Year | 3.79 |
EPS Estimate Next Year | 3.97 |
EPS Estimate Current Quarter | 0.93 |
EPS Estimate Next Quarter | 0.96 |
What analysts predicted
Upside of 7.7%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.2B | ↑ 8.32% |
Net Income | 269.6M | ↑ 91.67% |
Net Profit Margin | 12.22% | ↑ 5.32% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.3B | ↑ 13.49% |
Net Income | 261.4M | ↑ 3.74% |
Net Profit Margin | 11.17% | ↓ 1.05% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.6B | ↑ 8.66% |
Net Income | 236.7M | ↓ 11.59% |
Net Profit Margin | 9.09% | ↓ 2.08% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.8B | ↑ 13.0% |
Net Income | 309.2M | ↑ 36.72% |
Net Profit Margin | 10.99% | ↑ 1.9% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 3.0B | ↑ 14.69% |
Net Income | 548.0M | ↑ 91.22% |
Net Profit Margin | 18.33% | ↑ 7.34% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 3.4B | ↑ 13.54% |
Net Income | 670.6M | ↑ 23.56% |
Net Profit Margin | 19.95% | ↑ 1.62% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 765.7M | ↓ 6.99% |
Net Income | 116.6M | ↓ 23.09% |
Net Profit Margin | 15.23% | ↓ 3.19% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 820.1M | ↑ 7.01% |
Net Income | 170.7M | ↑ 46.22% |
Net Profit Margin | 20.81% | ↑ 5.58% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 828.4M | ↑ 2.1% |
Net Income | 178.2M | ↑ 5.53% |
Net Profit Margin | 21.51% | ↑ 0.7% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 866.6M | ↑ 4.86% |
Net Income | 165.6M | ↓ 6.83% |
Net Profit Margin | 19.11% | ↓ 2.4% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 924.0M | ↑ 6.35% |
Net Income | 167.6M | ↑ 0.95% |
Net Profit Margin | 18.14% | ↓ 0.97% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 919.1M | ↑ 0.0% |
Net Income | 166.8M | ↑ 0.0% |
Net Profit Margin | 18.14% | ↑ 0.0% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.2B | ↓ 0.08% |
Total Liabilities | 1.2B | ↓ 14.03% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↑ 3.02% |
Total Liabilities | 1.0B | ↓ 9.36% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.6B | ↑ 14.32% |
Total Liabilities | 1.2B | ↑ 17.16% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.9B | ↑ 11.74% |
Total Liabilities | 1.4B | ↑ 17.25% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.9B | ↑ 8.83% |
Total Liabilities | 1.1B | ↓ 15.21% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 4.7B | ↑ 20.03% |
Total Liabilities | 1.3B | ↑ 18.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.9B | ↑ 4.38% |
Total Liabilities | 1.1B | ↑ 72.9% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.1B | ↑ 3.78% |
Total Liabilities | 673.8M | ↓ 38.48% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.2B | ↑ 3.58% |
Total Liabilities | 1.1B | ↑ 69.67% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.5B | ↑ 7.44% |
Total Liabilities | 1.3B | ↑ 11.77% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 5.0B | ↑ 11.39% |
Total Liabilities | 1.5B | ↑ 14.93% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 5.0B | ↑ 0.0% |
Total Liabilities | 1.4B | ↑ 0.0% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 411.8M | ↑ 59.21% |
Investing Cash Flow | -110.9M | ↓ 48.08% |
Financing Cash Flow | -306.0M | ↑ 380.32% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 400.0M | ↑ 3.96% |
Investing Cash Flow | -66.0M | ↓ 36.29% |
Financing Cash Flow | -337.2M | ↑ 17.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 490.2M | ↑ 19.64% |
Investing Cash Flow | -311.1M | ↑ 360.29% |
Financing Cash Flow | -4.1M | ↓ 98.82% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 368.8M | ↓ 21.27% |
Investing Cash Flow | -346.2M | ↑ 16.45% |
Financing Cash Flow | -31.8M | ↑ 712.75% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 715.9M | ↑ 109.45% |
Investing Cash Flow | -503.1M | ↑ 56.79% |
Financing Cash Flow | -326.6M | ↑ 1009.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 239.3M | ↓ 15.4% |
Investing Cash Flow | -503.1M | ↑ 61.61% |
Financing Cash Flow | -52.3M | ↓ 837.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 136.9M | ↓ 42.83% |
Investing Cash Flow | -55.0M | ↓ 89.08% |
Financing Cash Flow | -18.0M | ↓ 65.66% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 215.8M | ↑ 59.34% |
Investing Cash Flow | -153.6M | ↑ 182.33% |
Financing Cash Flow | -84.7M | ↑ 376.69% |
Sell
Neutral
Buy
Dr. Reddy's Laboratories Ltd. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Dr. Reddy's Laboratories Ltd. | -2.03% | 8.81% | 20.2% | 18.14% | 110.13% |
Neurocrine Biosciences Inc. | -7.9% | -16.26% | 4.26% | 14.31% | 28.12% |
Haleon Plc Spon Ads | 4.13% | 28.4% | 27.47% | 42.78% | 42.78% |
Zoetis Inc. | 6.43% | 19.89% | 14.71% | 0.87% | 57.21% |
Viatris Inc. | -2.35% | -3.41% | 20.31% | -13.55% | -28.95% |
Catalent, Inc. | -0.21% | 6.86% | 37.82% | -53.05% | 26.35% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Dr. Reddy's Laboratories Ltd. | 20.02 | 20.02 | 4.58 | 3.79 | 0.21 | 0.11 | 0.01 | 1769.05 |
Neurocrine Biosciences Inc. | 34.6 | 34.6 | 0.26 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 34.42 | 34.42 | 1.51 | 0.4 | 0.07 | 0.04 | 0.01 | 1.82 |
Zoetis Inc. | 38.14 | 38.14 | 2.65 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 2.86 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Dr. Reddy's Laboratories Ltd. | Buy | $13.5B | 110.13% | 20.02 | 19.26% |
Neurocrine Biosciences Inc. | Buy | $11.6B | 28.12% | 34.6 | 16.0% |
Haleon Plc Spon Ads | Buy | $48.6B | 42.78% | 34.42 | 9.66% |
Zoetis Inc. | Buy | $88.3B | 57.21% | 38.14 | 26.29% |
Viatris Inc. | Hold | $13.6B | -28.95% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 26.35% | 211.02 | -23.81% |
Insights on Dr. Reddy's Laboratories Ltd.
Revenue is up for the last 6 quarters, 62.96B → 76.72B (in $), with an average increase of 3.8% per quarter
Netprofit is up for the last 3 quarters, 13.78B → 13.92B (in $), with an average increase of 0.5% per quarter
In the last 1 year, Catalent, Inc. has given 37.8% return, outperforming this stock by 17.6%
Robeco Institutional Asset Management BV
Royal Bank of Canada
Morgan Stanley - Brokerage Accounts
Renaissance Technologies Corp
BlackRock Inc
Aikya Investment Management Ltd
In the quarter ending December,2024. Dr. Reddy's Laboratories Ltd. has declared dividend of $0.48
Read MoreDr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, Telangana, India. Founded in 1984 by Dr. K. Anji Reddy, the company provides a wide range of pharmaceuticals in India and over 25 countries worldwide. Dr. Reddy's Laboratories operates in various segments, including generic medicines, active pharmaceutical ingredients (APIs), custom pharmaceutical services, biosimilars, and differentiated formulations. The company's portfolio includes products for therapeutic areas such as gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's Laboratories is listed on the NYSE under the ticker symbol RDY, making its American Depositary Receipts (ADRs) available to U.S. investors. Known for its commitment to innovation, quality, and affordability, Dr. Reddy's Laboratories continues to deliver comprehensive healthcare solutions and improve the lives of patients globally. Currently Dr. Reddy's Laboratories ADR has a market cap of $13.73 Billion. It has a P.E ratio of 0.0. The shares of Dr. Reddy's Laboratories ADR are trading at $79.45 .
Organization | Dr. Reddy's Laboratories Ltd. |
Employees | 27048 |
CEO | Mr. Gunupati Venkateswara Prasad B.E. |
Industry | Health Technology |